This is the second installment of something we’re making a regular habit: reading Tricycle Day each week and sharing what it means from where we sit (a physician-led ketamine clinic in Greenwood, Indiana), treating real patients with real conditions every day.
If you haven’t come across Tricycle Day yet, it’s one of the best resources we’ve found for following the psychedelic medicine space without the noise. They publish weekly, they cite their sources, and they write for people who want to actually think about this — not just scroll past a headline. We’d genuinely encourage you to subscribe and read it yourself. What we offer here is just our layer on top: the clinical lens, the Indiana context, and an honest opinion.
Here’s what we took away from their June 17 issue.
Who You Are Shapes What You Experience — in a Ketamine Chair and Everywhere Else
A study of more than 400 psychedelic users found that personality traits predict the intensity of sensory experiences during a session more than most people would expect. The biggest factor wasn’t how “open-minded” someone is. It was something called absorption: how readily a person gets pulled into their own inner world, whether that’s music, memory, or imagination.
That finding lands differently when you’ve done what we’ve done sat with thousands of patients through thousands of infusions. We’ve watched people with identical diagnoses and similar doses have profoundly different experiences in the same chair. Some go very deep, very fast. Others stay relatively grounded throughout. Neither is wrong. Both can be healing.
What the research is beginning to confirm is something good clinicians have always known: the person matters as much as the protocol. That’s why the conversation before a first infusion at AlphaOmega isn’t a checklist. It’s a real conversation about who you are, how you process hard things, what you’re hoping for, and what might come up. The better we understand you going in, the better we can support you through it.
For Hoosiers curious about ketamine therapy: don’t let uncertainty about what the experience will “be like” keep you from exploring it. It looks different for everyone, and that’s by design. What’s consistent is the outcome and those we can speak to directly. That’s why we have designed the Brain Health Reboot: IV ketamine therapy + integration education.
A Federal Bill That Could Change Everything for Psychedelic Medicine
A bill was recently introduced in Congress that would rewrite how federal law defines “accepted medical use” the very phrase that has kept psilocybin locked in Schedule I since 1970. Under the proposed framework, if a state has authorized a substance medically, licensed practitioners are using it, and state regulators have evaluated it rigorously, it would qualify. States like Oregon and Colorado, which already run regulated psilocybin programs, could effectively trigger federal rescheduling through their existing programs.
We won’t predict whether this passes. What we will say is that the environment around this legislation is unlike anything we’ve seen in our careers. A presidential executive order directing $50 million toward psychedelic research. State senates passing psychedelic bills unanimously. Bipartisan support in Congress for the first time. This isn’t a fringe conversation anymore.
What does it mean for Indiana specifically? Indiana doesn’t have a state psychedelic program, and there’s no immediate indication that’s changing. But we’ve watched other areas of medicine including ketamine itself go from “experimental” to “standard of care” faster than anyone anticipated. We think it’s important for our patients to understand the full arc of where this is heading, even if the timeline is uncertain.
If you want to follow this closely as it develops, Tricycle Day covers every legislative development in real time. Their archive alone is worth subscribing for.
MDMA for PTSD Is Still Alive — and Now Better Funded Than Ever
After the FDA rejected the first MDMA-assisted therapy application for PTSD in 2024, the company behind it now rebranded as Resilient Pharmaceuticals was recapitalized with $100 million from outside investors. One of those investors recently saw his net worth grow substantially with a major IPO, meaning the financial backing behind MDMA’s path to approval just got considerably deeper.
Here’s our take on why this matters for our patients: PTSD is one of the conditions we treat most at AlphaOmega, and it’s one where ketamine consistently produces results that surprise people. The research on MDMA-assisted therapy in PTSD has also shown meaningful outcomes. These aren’t competing treatments in our minds they’re part of a broader shift toward medicines that actually work on the brain’s trauma response rather than just managing symptoms.
More investment in this space means more trials, more data, and eventually more options for people who’ve tried everything and haven’t found relief. That’s good for our patients. That’s good for Indiana veterans, first responders, and survivors who’ve been waiting a long time for additional treatment options.
Our Honest Take
The theme running through everything in this week’s Tricycle Day and honestly through most weeks is that the field is growing up. The science is getting more nuanced. The policy is moving. The money is following. And the questions are getting better.
At AlphaOmega, we’ve believed since the beginning that the brain has more capacity to heal than medicine has given it credit for. We still believe that. And we think the next few years are going to show a lot more people what we’ve already seen in our clinic: that with the right treatment, at the right time, real recovery is possible.
Read Tricycle Day’s full June 17 issue here, and subscribe if you want to stay current. It’s the best weekly briefing we’ve found on where this field is going.
And if any of this has you thinking about your own situation whether you’ve been dealing with depression, anxiety, PTSD, or something you haven’t been able to name reach out and let’s talk. That’s what we’re here for.